MDxHealth (NASDAQ:MDXH – Get Free Report) and Movano (NASDAQ:MOVE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.
Insider and Institutional Ownership
16.6% of Movano shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 10.4% of Movano shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares MDxHealth and Movano”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $107.88 million | 1.31 | -$33.52 million | ($0.67) | -4.27 |
| Movano | $1.01 million | 16.20 | -$23.73 million | ($10.83) | -1.33 |
Movano has lower revenue, but higher earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Movano, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for MDxHealth and Movano, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 0 | 4 | 0 | 2.60 |
| Movano | 1 | 0 | 0 | 0 | 1.00 |
MDxHealth currently has a consensus price target of $7.75, suggesting a potential upside of 170.98%. Given MDxHealth’s stronger consensus rating and higher possible upside, equities analysts plainly believe MDxHealth is more favorable than Movano.
Profitability
This table compares MDxHealth and Movano’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -31.07% | -1,078.01% | -21.71% |
| Movano | -3,409.60% | -647.91% | -225.03% |
Risk & Volatility
MDxHealth has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Movano has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Summary
MDxHealth beats Movano on 8 of the 14 factors compared between the two stocks.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
About Movano
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
